The adalimumab market is expected to show negative growth during the forecast period 2020-2026. Adalimumab is sold by AbbVie Inc., under the brand name of Humira. It was the first approved treatment of rheumatoid arthritis in the US in 2002 and in the EU in 2003. Humira is a biological therapy administered as a subcutaneous injection. In 2019, Humira accounted for around 58% of the total net revenue of AbbVie Inc., with revenue of $19.1 billion as compared to $19.9 billion in 2018. The high cost of the Humira is able to provide a significant market to the adalimumab market. It is due to the high annual costs of the drug. For instance, in the US, the annual cost of using Humira was around $19,000 in 2012 which has risen to around $38,000 with rebates in 2018 and about $50,000 without rebates.

Increasing prevalence of arthritis, Crohn’s diseases, and increasing per capita healthcare expenditure in the emerging economies, are some of the factors contributing to the growth of the adalimumab market, however; loss of branded drug patent and approval to biosimilars are among the key factors for the downfall in revenue of the drug. AbbVie Inc. has lost its EU patent in 2017 however the company obtained Supplementary Protection Certificates (SPCs) which offered patent protection until 16th October 2018 to the company. Moreover, the initial US composition patent of the drug expired in December 2016. 

It was expected that after the expiration of the patent, multiple global companies will start manufacturing biosimilar of Humira; however, AbbVie Inc. is still continuing its monopoly in the market. It is due to the fact, that AbbVie Inc. has made an agreement with other biosimilar manufacturing companies for not to manufacture biosimilar (such as Boehringer Ingelheim International GmbH, Novartis AG, Amgen Inc.) till 2023 due to which the company is expected to maintain its monopoly for next three to four years in the US market, which is the largest market for adalimumab globally. However, after 2023, a significant drop in the Humira revenue is expected, which will provide a negative CAGR to the market during the forecast period. Moreover, the availability of an alternative of adalimumab is also expected to restrain market growth in the near future. Drugs such as Cimzia, Enbrel, Remicade, and Simponi are available in the market to treat rheumatoid arthritis and Crohn's disease. 

Market Segmentation

The global adalimumab market is segmented based on disease and type. On the basis of disease, the market is segmented into rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and others. Rheumatoid arthritis is expected to hold the major market share during the forecast period. By type, the market is bifurcated into branded and generic drugs. Till 2023, branded drugs are expected to have a major market share and a significant market growth will be witnessed until 2023 however after that a steep downfall is expected in the branded drug revenue. However, generic drugs are expected to grow with a lucrative growth rate during the forecast period.  

Global Adalimumab Market Share by Disease, 2019 (%)

Regional Outlook

On the basis of geography, the global adalimumab market is segmented into four major regions that include North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America holds the major market share during the forecast period as around 77% of the total Humira revenue was generated from the US in 2019. Europe is expected to show a modest growth rate in the market as companies are shifting from branded Humira to adalimumab biosimilars. Asia-Pacific is expected to showcase significant growth during the forecast period. The availability of biosimilars of the Humira is expected to provide significant growth to the region. 

Global Adalimumab Market Growth, by Region 2020-2026

Market Players Outlook

The adalimumab market is consolidated in nature and a few major market players hold more than 95% of the global market share. The major players operating in the market include AbbVie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH. The market players are adopting growth strategies including mergers and acquisitions, product launches, and partnerships & collaborations with hospitals to gain a competitive edge in the market. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Adalimumab market. 
• Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.